Valproyl-dephosphoCoA: A novel metabolite of valproate formed in vitro in rat liver mitochondria

Drug Metabolism and Disposition

Volumn 32, Issue 11, 2004, Pages 1304-1310

  Silva, Margarida F B ^a,b   IJlst, Lodewijk ^a   Allers, Paul ^c   Jakobs, Cornelis ^d   Duran, Marinus ^a   Tavares De Almeida, Isabel ^b   Wanders, Ronald J A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROYL DEPHOSPHOCOENZYME A;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEPHOSPHORYLATION; DRUG METABOLISM; FAST ATOM BOMBARDMENT MASS SPECTROMETRY; FATTY ACID OXIDATION; IN VITRO STUDY; LIVER MITOCHONDRION; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACYL COENZYME A; ANIMALS; CARBOHYDRATE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPID PEROXIDATION; MALE; MITOCHONDRIA, LIVER; MOLECULAR SEQUENCE DATA; RATS; RATS, WISTAR; VALPROIC ACID;

ANIMALIA;

EID: 6944246254     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd...     Document Type: Article

References (29)

1. Abbott FS and Anari MR (1999) Chemistry and biotransformation, in Valproate (Milestones in Drug Therapy) (Löscher W ed) pp 47-75, Birkhäuser Verlag, Basel, Switzerland.
2. Atkinson DE (1977) Cellular Energy Metabolism and Its Regulation. Academic Press, New York.
3. Bunik VI (2003) 2-Oxo acid dehydrogenase complexes in redox regulation. Eur J Biochem 270:1036-1042.
4. Daugherty M, Polanuyer B, Farrell M, Scholle M, Lykidis A, de Crecy-Lagard V, and Osterman A (2002) Complete reconstitution of the human coenzyme A biosynthetic pathway via comparative genomics. J Biol Chem 277:21431-21439.
5. Davis R, Peters DH, and McTavish D (1994) Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47:332-372.
6. Gopaul SV, Farrell K, and Abbott FS (2000) Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab Dispos 28:823-832.
7. Gopaul SV, Tang W, Farrell K, and Abbott FS (2003) Amino acid conjugates: metabolites of 2-propylpentanoic acid (valproic acid) in epileptic patients. Drug Metab Dispos 31:114-121.
8. Graf WD, Oleinik OE, Glauser TA, Maertens P, Eder DN, and Pippenger CE (1998) Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. Neuropediatrics 29:195-201.
9. Granneman GR, Wang SI, Machinist JM, and Kesterson JW (1984) Aspects of the metabolism of valproic acid. Xenobiotica 14:375-387.
10. Ito M, Ikeda Y, Arnez JG, Finochiaro G, and Tanaka K (1990) The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. Biochim Biophys Acta 1034:213-218.
11. Kassahun K, Hu P, Grillo MP, Davis MR, Jin L, and Baillie TA (1994) Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem-Biol Interact 90:253-275.
12. König SA, Schenk M, Sick C, Holm E, Heubner C, Weiss A, König I, and Helmann R (1999) Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia 40:1036-1040.
13. König SA, Siemes H, Bläker F, Boenigk E, Groß-Selbek G, Hanefeld F, Haas N, Köhler B, Koelfen W, Korinthenberg R, et al. (1994) Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 35:1005-1015.
14. LaNoue KF, Walajtys EI, and Williamson JR (1973) Regulation of glutamate metabolism and interactions with the citric acid cycle in rat heart mitochondria. J Biol Chem 248:7171-7183.
15. Li J, Norwood DL, Mao LF, and Schultz H (1991) Mitochondrial metabolism of valproic acid. Biochemistry 30:388-394.
16. Nau H, Wittfoht W, Schaffer H, Jakobs C, Rating D, and Helge H (1981) Valproic acid and several metabolites: quantitative determination in serum, urine, breast milk and tissues by gas chromatography-mass spectrometry using selected ion monitoring. J Chromatogr 226:69-78.
17. Peterson KL, Peterson KM, and Srivastava DK (1998) Thermodynamics of ligand binding and catalysis in human liver medium-chain acyl-CoA dehydrogenase: comparative studies involving normal and 3′-dephosphorylated C8-CoAs and wild type and Asn191→Ala (N191A) mutant enzymes. Biochemistry 37:12659-12671.
18. Peterson KL and Srivastava DK (1997) Functional role of a distal (3′-phosphate) group of CoA in the recombinant human liver medium-chain acyl-CoA dehydrogenase-catalysed reaction. Biochem J 325:751-760.
19. Radatz M and Nau H (1999) Toxicity, in Milestones in Drug Therapy Valproate (Löscher W ed) pp 91-128, Birkhäuser Verlag, Basel, Switzerland.
20. Rasmussen JT, Börchers T, and Knudsen J (1990) Comparison of the binding affinities of acyl-CoA-binding protein and fatty-acid-binding protein for long-chain acyl-CoA esters. Biochem J 265:849-855.
21. Rettenmeier AW, Howald WN, Levy RH, Witek DJ, Gordon HP, Porubek DJ, and Baillie TA (1989) Quantitative metabolic profiling of valproic acid in humans using automated gas chromatographic/mass spectrometric techniques. Biomed Environ Mass Spectrom 18:192-199.
22. Silva MFB, Ruiter JPN, IJlst L, Allers P, Ten Brink H, Jakobs C, Duran M, Tavares de Almeida I and Wanders RJA (2001) Synthesis and intramitochondrial levels of valproyl-CoA metabolites. Anal Biochem 290:60-67.
23. Silva MFB, Ruiter JPN, Overmars H, Bootsma AH, van Gennip AH, Jakobs C, Duran M, Tavares de Almeida I, and Wanders RJA (2002) Complete β-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J 362:755-760.
24. Skrede S and Halvorsen O (1979) Mitochondrial biosynthesis of coenzyme A. Biochem Biophys Res Commun 91:1536-1542.
25. Smith PK, Krohn RI, Hermanson GT, Malliu AK, Gartner FH, Provenzano MD, Fugimoto EK, Goede NM, Olson BJ, and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
26. Stephens JR and Levy RH (1992) Valproate hepatotoxicity syndrome: hypotheses of pathogenesis. Pharm Weekbl Sci 14 (3A):118-121.
27. Tang W and Abbott FS (1996) Bioactivation of atoxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates. Chem Res Toxicol 9:517-526.
28. Tatsuhara T, Muro H, Matsuda Y, and Imai Y (1987) Determination of VPA and its metabolites by GC-MS with SIM. J Chromatogr 399:183-195.
29. Zubay G (1998) Metabolic strategies, in Biochemistry, pp 267-281, Wm. C. Brown Publishers. Dubuque, 1A.